868049-73-4

Basic information

• Product Name: 1-(3,5-difluorophenyl)-2-methylpropan-2-ol
• Synonyms: 1-(3,5-difluorophenyl)-2-methylpropan-2-ol
• CAS NO: 868049-73-4
• Molecular Weight: 186.201
• Mol File: 868049-73-4.mol

Chemical Properties

• CAS DataBase Reference: 1-(3,5-difluorophenyl)-2-methylpropan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,5-difluorophenyl)-2-methylpropan-2-ol(868049-73-4)
• EPA Substance Registry System: 1-(3,5-difluorophenyl)-2-methylpropan-2-ol(868049-73-4)

Safety Data

• Hazardous Substances Data: 868049-73-4(Hazardous Substances Data)

Upstream product

• 67-64-1 acetone 
• 210530-70-4 methyl 2-(3,5-difluorophenyl)acetate 
• 75-16-1 methylmagnesium bromide 
• 105184-38-1 3,5-difluorophenyl acetic acid 
• 917-64-6 methyl magnesium iodide 
• 141776-91-2 1-bromomethyl-3,5-difluoro-benzene 

Downstream Products

• 1373042-00-2 C₁₆H₂₄F₂N₂O 
• 1357290-84-6 KMI-1898 
• 1373042-09-1 C₁₉H₂₈F₂N₂O 
• 1395993-35-7 1-[3,5-difluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-2-methylpropan-2-ol 

Relevant articles and documents

PYRIDINEAMINE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS

The present disclosure describes pyridineamine compounds, as well as their compositions and methods of use. The compounds inhibit the activity of the Pim kinases, and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer, immune disorders and other diseases. Formula (I).

Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design

Previously reported pentapeptidic BACE1 inhibitors, designed using a substrate-based approach, were used as lead compounds for the further design of non-peptidic BACE1 inhibitors. Although these peptidic and non-peptidic inhibitors, with a hydroxymethylcarbonyl isostere as a substrate transition-state mimic, exhibited potent BACE1 inhibitory activities, their molecular-sizes appeared a little too big (molecular weight of >600 daltons) for developing practical anti-Alzheimer's disease drugs. To develop lower weight BACE1 inhibitors, a series of tripeptidic BACE1 inhibitors were devised using a design approach based on the conformation of a virtual inhibitor bound to the BACE1 active site, also called 'in-silico conformational structure-based design'. Although these tripeptidic BACE1 inhibitors contained some natural amino acid residues, they are expected to be useful as lead compounds for developing the next generation BACE1 inhibitors, due to their low molecular size and unique structural features compared with previously reported inhibitors.

Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists

Novel β2-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the β2-adrenoceptor with a high β1/β2-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the β2-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h.

Novel medicament combinations for the treatment of respiratory diseases

The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claim

Aerosol formulation for the inhalation of beta-agonists

The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula 1 wherein the groups R1, R2, R3 and X? may have the meanings given in the claims a

Novel medicaments for the treatment of respiratory diseases

The present invention relates to the use of the compounds of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claims and in the specification, for preparing a pharmaceutical composition